Extra · Adult education · California context
A quiet desk for adults who want clear writing about cannabis — what peer-reviewed research actually supports, what remains mixed, and how plant chemistry (not folk strain names) shapes effects. This is education, not a clinic visit and not a product pitch.
Essays
01 · Health evidence
Pain, chemo nausea, MS spasticity, sleep/anxiety where evidence exists — with harms, dependence risk, and adolescent/pregnancy warnings kept in frame.
02 · Plant chemistry
Myrcene, limonene, pinene, linalool, β-caryophyllene and friends — aroma molecules, 2025 myrcene pain-model science, and a cautious take on the entourage hypothesis.
03 · Labels vs science
Why morphology heritage is a weak predictor of effects, why hybrids dominate the market, and why chemotype (THC/CBD/terpenes) matters more.
In California, adults can legally possess and purchase cannabis under state law in licensed channels — but federal status, workplace rules, driving laws, and health risks still apply. These pages cite reviews and clinical literature so you can weigh claims without the marketing fog.
Strong evidence means consistent signals from randomized trials or high-quality systematic reviews. Mixed or limited means interesting findings that do not yet support sweeping claims. Nothing here is a prescription, dosing guide, or sourcing advice.
A 2017–2024 analysis in the Journal of Cannabis Research (California Health Interview Survey adults) found past-year and past-month cannabis use largely stable across the years spanning the start of licensed adult-use retail. Methods shifted: among past-month consumers, combustible use (joints, pipes, or bongs) fell from about 71% to 58%, while edible use rose from about 40% to 54%. Past-month prevalence increased in adults aged 40–59 and in those 75 and older, while remaining essentially unchanged among the youngest adults in the study window (Corroon, Bandoli et al. · DOI 10.1186/s42238-026-00475-z).
For market literacy only — not shopping advice — California Department of Cannabis Control / industry reporting put licensed retail sales at roughly $956.7 million in Q1 2026, with vape products leading dollar sales ahead of packaged flower (MJBizDaily summary of DCC/CDTFA data). Category leadership in sales dashboards is not a health ranking.
Disclaimer. Educational content only — not medical, legal, or therapeutic advice. Talk with a qualified clinician about personal health decisions, especially pregnancy, adolescence, mental-health history, or prescription drugs.